Your browser doesn't support javascript.
loading
Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation.
Deng, Xianding; Garcia-Knight, Miguel A; Khalid, Mir M; Servellita, Venice; Wang, Candace; Morris, Mary Kate; Sotomayor-González, Alicia; Glasner, Dustin R; Reyes, Kevin R; Gliwa, Amelia S; Reddy, Nikitha P; Martin, Claudia Sanchez San; Federman, Scot; Cheng, Jing; Balcerek, Joanna; Taylor, Jordan; Streithorst, Jessica A; Miller, Steve; Kumar, G Renuka; Sreekumar, Bharath; Chen, Pei-Yi; Schulze-Gahmen, Ursula; Taha, Taha Y; Hayashi, Jennifer; Simoneau, Camille R; McMahon, Sarah; Lidsky, Peter V; Xiao, Yinghong; Hemarajata, Peera; Green, Nicole M; Espinosa, Alex; Kath, Chantha; Haw, Monica; Bell, John; Hacker, Jill K; Hanson, Carl; Wadford, Debra A; Anaya, Carlos; Ferguson, Donna; Lareau, Liana F; Frankino, Phillip A; Shivram, Haridha; Wyman, Stacia K; Ott, Melanie; Andino, Raul; Chiu, Charles Y.
Afiliación
  • Deng X; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Garcia-Knight MA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Khalid MM; Department of Microbiology and Immunology, University of California San Francisco, California, USA.
  • Servellita V; Department of Medicine, University of California San Francisco, California, USA.
  • Wang C; Gladstone Institute of Virology, San Francisco, California, USA.
  • Morris MK; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Sotomayor-González A; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Glasner DR; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Reyes KR; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Gliwa AS; California Department of Public Health, Richmond, California, USA.
  • Reddy NP; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Martin CSS; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Federman S; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Cheng J; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Balcerek J; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Taylor J; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Streithorst JA; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Miller S; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Kumar GR; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Sreekumar B; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Chen PY; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Schulze-Gahmen U; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA.
  • Taha TY; Laboratory for Genomics Research, University of California San Francisco, California, USA.
  • Hayashi J; Department of Medicine, University of California San Francisco, California, USA.
  • Simoneau CR; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • McMahon S; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Lidsky PV; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Xiao Y; Department of Laboratory Medicine, University of California San Francisco, California, USA.
  • Hemarajata P; Department of Medicine, University of California San Francisco, California, USA.
  • Green NM; Gladstone Institute of Virology, San Francisco, California, USA.
  • Espinosa A; Department of Medicine, University of California San Francisco, California, USA.
  • Kath C; Gladstone Institute of Virology, San Francisco, California, USA.
  • Haw M; Department of Medicine, University of California San Francisco, California, USA.
  • Bell J; Gladstone Institute of Virology, San Francisco, California, USA.
  • Hacker JK; Department of Medicine, University of California San Francisco, California, USA.
  • Hanson C; Gladstone Institute of Virology, San Francisco, California, USA.
  • Wadford DA; Department of Medicine, University of California San Francisco, California, USA.
  • Anaya C; Gladstone Institute of Virology, San Francisco, California, USA.
  • Ferguson D; Department of Medicine, University of California San Francisco, California, USA.
  • Lareau LF; Gladstone Institute of Virology, San Francisco, California, USA.
  • Frankino PA; Department of Medicine, University of California San Francisco, California, USA.
  • Shivram H; Gladstone Institute of Virology, San Francisco, California, USA.
  • Wyman SK; Department of Medicine, University of California San Francisco, California, USA.
  • Ott M; Gladstone Institute of Virology, San Francisco, California, USA.
  • Andino R; Department of Microbiology and Immunology, University of California San Francisco, California, USA.
  • Chiu CY; Department of Microbiology and Immunology, University of California San Francisco, California, USA.
medRxiv ; 2021 Mar 09.
Article en En | MEDLINE | ID: mdl-33758899
We identified a novel SARS-CoV-2 variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged around May 2020 and increased from 0% to >50% of sequenced cases from September 1, 2020 to January 29, 2021, exhibiting an 18.6-24% increase in transmissibility relative to wild-type circulating strains. The variant carries 3 mutations in the spike protein, including an L452R substitution. Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants. Antibody neutralization assays showed 4.0 to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California associated with decreased antibody neutralization warrants further investigation.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: MedRxiv Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: MedRxiv Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos